Vanqua Bio Valuation, Funding & Investors

Character Biosciences is a San Francisco-headquartered therapeutics developer applying genomics, longitudinal imaging, and machine learning to uncover disease progression drivers. Collaborations with health systems build phenotyped cohorts for research into ophthalmology and neurodegeneration, yielding targeted drug candidates.

Valo Health is a Boston-headquartered biotech firm that integrates multimodal human data into its Opal Computational Platform for drug discovery. The platform analyzes real-world evidence, clinical, and molecular datasets to advance therapies in cardiovascular, metabolic, renal, oncology, and neurodegenerative areas. Valo maintains offices in Lexington and New York City alongside its Boston base. Launched in 2018 by Flagship Pioneering, it collaborates with AstraZeneca on heart failure programs and Bayer on cardiovascular targets. The company processes petabytes of data to nominate drug candidates and optimize trials.

ReCode Therapeutics is a Menlo Park, California-headquartered clinical-stage genetic medicines company developing mRNA and gene-edited therapies. Its SORT LNP platform enables extrahepatic delivery to lungs and other organs for diseases like primary ciliary dyskinesia and cystic fibrosis. ReCode advances RCT2100 into Phase II trials and partners with CRISPR pioneers for targeted corrections.

Hexagon Bio is a Menlo Park-based biotechnology company engineering small molecule therapeutics from fungal genomes. Its platform merges data science and synthetic biology to identify drug candidates targeting unmet needs in infectious diseases and oncology through natural product optimization.

Clear Labs is a Woburn-based genomics company delivering next-generation sequencing through Clear Dx for pathogen detection in infectious diseases and Clear Safety for food safety contaminants like Salmonella and E. coli. Its platforms support FDA-compliant surveillance and supply chain testing for food producers and public health agencies.

Readline is a Shenzhen-headquartered biopharmaceutical firm pioneering enzyme-directed evolution for green manufacturing of active pharmaceutical ingredients. Specializing in peptides, carbohydrates, and nucleic acids, it supplies intermediates for medicines, cosmetics, animal feed, and biological pesticides, emphasizing sustainable production processes at industrial scale.

Inceptive is a biotechnology firm that engineers RNA molecules through deep learning models refined by high-throughput wet-lab experiments. Headquartered in South San Francisco, the company builds platforms for designing mRNA vaccines, gene therapies, and protein therapeutics. Its Evo 2.0 model generates novel RNA sequences with specified properties, accelerating development of treatments for infectious diseases and rare genetic disorders.

Abclon Inc is engaged in the research and development of antibody drugs. Its business sector is divided into Antibody drug and Bio CRO.

Vedanta Biosciences is a Cambridge, Massachusetts-based biotechnology company engineering microbiome immunotherapies for autoimmune, inflammatory, and infectious diseases. It develops consortia of live bacteria selected via proprietary assays from human donor samples, manufactured in cGMP facilities for oral administration. Vedanta's lead candidate VE202 advances in Phase 2 for graft-versus-host disease, with prior programs partnered to Janssen for Crohn's disease. Founded in 2010 as Seres spin-out, it maintains a library of over 1,000 bacterial strains and datasets from interventional studies.

City Therapeutics engineers enhanced small-interfering RNAs for RNAi therapeutics targeting liver, muscle, and CNS diseases from its Boston headquarters. Founded in 2023, the biopharma advances a pipeline of siRNA candidates improving delivery and potency, backed by ARCH Venture Partners and Takeda. Its platform conjugates lipids and GalNAc for extrahepatic tissue targeting in metabolic and neuromuscular disorders.

Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.

Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company’s development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.